



[Go to Product page](#)

Datasheet for ABIN6991412 **anti-CIITA antibody (N-Term)**

Overview

| | |
|----------------------|--|
| Quantity: | 0.1 mg |
| Target: | CIITA |
| Binding Specificity: | AA 120-170, N-Term |
| Reactivity: | Human, Mouse, Rat |
| Host: | Rabbit |
| Clonality: | Polyclonal |
| Conjugate: | This CIITA antibody is un-conjugated |
| Application: | Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF) |

Product Details

| | |
|---------------|---|
| Immunogen: | CIITA antibody was raised against a 16 amino acid synthetic peptide near the amino terminus of human CIITA. The immunogen is located within amino acids 120 - 170 of CIITA. |
| Isotype: | IgG |
| Purification: | CIITA Antibody is affinity chromatography purified via peptide column. |

Target Details

| | |
|-------------------|--|
| Target: | CIITA |
| Alternative Name: | CIITA (CIITA Products) |
| Background: | CIITA Antibody: CIITA contains an acidic transcriptional activation domain, four LRRs (leucine-rich repeats) and a GTP binding domain. It is located in the nucleus and acts as a positive |

Target Details

regulator of class II major histocompatibility complex gene transcription, and is referred to as the "master control factor" for the expression of these genes. CIITA also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction.

Molecular Weight: Predicted: 124 kDa

Observed: 125 kDa

Gene ID: 4261

UniProt: [P33076](#)

Pathways: [Cancer Immune Checkpoints](#)

Application Details

Application Notes: CIITA antibody can be used for detection of CIITA by Western blot at 1 μ g/mL. Antibody can also be used for immunohistochemistry starting at 10 μ g/mL. For immunofluorescence start at 20 μ g/mL.

Antibody validated: Western Blot in rat samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: CIITA Antibody is supplied in PBS containing 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling

Storage: -20 °C, 4 °C

Storage Comment: CIITA antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.